A study by Fukudo et al. [53] showed that adequate blood levels of REG, but also of its metabolites, were significant for progression-free survival (PSF) in patients with advanced metastatic colorectal cancer, gastrointestinal stromal tumor, and hepatocellular carcinoma. This evidence concerns the gene REG1A and metastatic colorectal cancer.